3-b]pyridazin-3-yl]sulfanyl}quinoline Uses, Dosage, Side Effects and more
A MET receptor tyrosine kinase inhibitor.
| Trade Name | 3-b]pyridazin-3-yl]sulfanyl}quinoline |
| Generic | SGX-523 |
| SGX-523 Other Names | 6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline |
| Type | |
| Formula | C18H13N7S |
| Weight | Average: 359.408 Monoisotopic: 359.095314141 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in solid tumors and cancer/tumors (unspecified).
How 3-b]pyridazin-3-yl]sulfanyl}quinoline works
SGX523 is selective inhibitor of the receptor tyrosine kinase MET. MET is implicated in development and progression of cancer. SGX523 ihibits MET autophosphorylation and signalling, as well as activates cysteine-aspartic acid protease 3 (caspase 3), an enzyme which is part of the apoptosis signalling cascade.
